Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00459342
First received: April 9, 2007
Last updated: April 29, 2014
Last verified: December 2012
  Purpose

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.


Condition Intervention Phase
Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Drug: dasatinib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Dasatinib in Non Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Objective response defined as participants with Complete Response (CR) or Partial Response (PR) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RECIST definitions are Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Response measured by tumor size on computed tomography scans and by metabolic activity on positron emission tomography scans.

  • Progression-free Survival (PFS) [ Time Frame: Time from start of treatment to time of progression or death, assessed at 2 months ] [ Designated as safety issue: No ]
    PFS is defined as the duration of time from start of treatment to time of progression or death.


Secondary Outcome Measures:
  • Overall Survival [ Time Frame: Time from start of treatment to death from any cause, assessed up to 5 years ] [ Designated as safety issue: No ]
    Number of participants still living, measured from start of treatment to death from any cause, assessed up to 5 years using Kaplan-Meier.

  • Time to Progression [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    Time in months from baseline assessment to disease progression or death for any reason, up to 5 years.


Enrollment: 35
Study Start Date: March 2007
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: dasatinib
Given orally
Other Names:
  • BMS-354825
  • Sprycel

Detailed Description:

PRIMARY OBJECTIVES:

I. Determine the progression-free survival at 12 weeks in patients with stage IIIB or IV or recurrent non-small cell lung cancer treated with dasatinib.

SECONDARY OBJECTIVES:

I. Determine the rate of response in patients treated with this drug. II. Examine the relationship between clinical response to this drug and epidermal growth factor receptor (EGFR) mutational status, EGFR copy number, and pSrc expression levels in pre-treatment tumor biopsies.

III. Determine the toxicity of this drug.

OUTLINE:

Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Previously obtained paraffin-embedded tumor tissue samples are analyzed by polymerase chain reaction and fluorescent in situ hybridization (FISH) for epidermal growth factor receptor and by immunohistochemistry for pSrc expression.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Platelet count >= 100,000/mm^3
  • Histologically or cytologically confirmed non-small cell lung cancer meeting 1 of the following criteria:

    • Stage IV disease
    • Stage IIIB disease with pleural effusion
    • Recurrent disease after surgery or radiotherapy
  • Measurable disease, defined as >= 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan
  • Previously treated brain metastasis allowed, provided there is no bleeding, no midline shift, no need for steroids or anti-convulsants, and no symptoms
  • Must agree to obtain residual tumor tissue available from the existing diagnostic biopsy tumor tissue
  • ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100%
  • Life expectancy > 12 weeks
  • WBC >= 3,000/mm^3
  • Absolute neutrophil count >= 1,500/mm^3
  • Bilirubin =< 1.5 times upper limit of normal (ULN)
  • AST and ALT =< 2.5 times ULN
  • Creatinine =< 3 times ULN OR Creatinine clearance >= 60 mL/min
  • No uncontrolled congestive heart failure or potentially life-threatening arrhythmia
  • No angina at rest
  • No neuropathy >= grade 2
  • No chronic diarrhea or history of inflammatory bowel disease
  • No history of pulmonary fibrosis (other than in an irradiated field)
  • No other concurrent serious medical illness
  • O2 saturation > 92% on room air
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of allergic reactions to compounds of similar chemical or biological composition to dasatinib
  • No QTc prolongation (i.e., QTC >= 480 msec) or other significant ECG abnormalities that could lead to adverse effects if the QTc interval were prolonged
  • No medical condition that impairs the ability to swallow, retain, or absorb dasatinib including, but not limited to, any of the following:

    • Gastrointestinal tract disease resulting in an inability to take oral medication, requirement for IV alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease
  • No myocardial infarction or ventricular tachyarrhythmia within the past 6 months
  • LVEF normal
  • No major conduction abnormality (unless cardiac pacemaker is present)
  • No ongoing or active infection
  • No history of significant bleeding disorder (congenital [von Willebrand's disease] or acquired [antifactor VIII antibodies])
  • No psychiatric illness or social situation that would preclude study compliance
  • No prior chemotherapy or biologic therapy for recurrent or metastatic non-small cell lung cancer
  • Adjuvant cytotoxic chemotherapy after surgical resection or chemotherapy with radiation for locally advanced disease (curative intent) allowed provided disease recurrence >= 3 months after completion of last chemotherapy dose
  • Measurable disease must be outside the radiotherapy port OR clearly growing inside the port
  • No prior radiotherapy to >= 25% of the marrow-containing skeleton
  • At least 7 days since prior and no concurrent medications that are inhibitors or inducers of CYP3A4
  • At least 7 days since prior and no concurrent agents with proarrhythmic potential
  • No other concurrent investigational agents
  • No other concurrent anticancer agents or therapies
  • No concurrent antiretroviral therapy for HIV-positive patients
  • No concurrent systemic antacids (H2 receptor antagonists and proton pump inhibitors)
  • Locally acting antacids allowed except for 2 hours before and after dasatinib administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00459342

Locations
United States, Texas
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Investigators
Principal Investigator: Faye Johnson M.D. Anderson Cancer Center
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00459342     History of Changes
Other Study ID Numbers: NCI-2009-00225, NCI-2009-00225, CDR0000538668, 2006-0593, 2006-0593, 7798, N01CM62202, P30CA016672
Study First Received: April 9, 2007
Results First Received: November 1, 2013
Last Updated: April 29, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Dasatinib
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors

ClinicalTrials.gov processed this record on November 27, 2014